Literature DB >> 20038718

Sources of bias in specimens for research about molecular markers for cancer.

David F Ransohoff1, Margaret L Gourlay.   

Abstract

Claims about the diagnostic or prognostic accuracy of markers often prove disappointing when "discrimination" found between cancers versus normals is due to bias, a systematic difference between compared groups. This article describes a framework to help simplify and organize current problems in marker research by focusing on the role of specimens as a source of bias in observational research and using that focus to address problems and improve reliability. The central idea is that the "fundamental comparison" in research about markers (ie, the comparison done to assess whether a marker discriminates) involves two distinct processes that are "connected" by specimens. If subject selection (first process) creates baseline inequality between groups being compared, then laboratory analysis of specimens (second process) may erroneously find positive results. Although both processes are important, subject selection more fundamentally influences the quality of marker research, because it can hardwire bias into all comparisons in a way that cannot be corrected by any refinement in laboratory analysis. An appreciation of the separateness of these two processes-and placing investigators with appropriate expertise in charge of each-may increase the reliability of research about cancer biomarkers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038718      PMCID: PMC2816003          DOI: 10.1200/JCO.2009.25.6065

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  41 in total

1.  Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.

Authors:  A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 2.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

Review 3.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.

Authors:  Richard Simon; Michael D Radmacher; Kevin Dobbin; Lisa M McShane
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

4.  Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

Authors:  D A Ahlquist; J E Skoletsky; K A Boynton; J J Harrington; D W Mahoney; W E Pierceall; S N Thibodeau; A P Shuber
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

5.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

6.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Authors:  Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

7.  Translation of highly promising basic science research into clinical applications.

Authors:  Despina G Contopoulos-Ioannidis; Evangelia Ntzani; John P A Ioannidis
Journal:  Am J Med       Date:  2003-04-15       Impact factor: 4.965

8.  DNA integrity as a potential marker for stool-based detection of colorectal cancer.

Authors:  Kevin A Boynton; Ian C Summerhayes; David A Ahlquist; Anthony P Shuber
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

9.  Cancer. Developing molecular biomarkers for cancer.

Authors:  David F Ransohoff
Journal:  Science       Date:  2003-03-14       Impact factor: 47.728

10.  Markers for early detection of cancer: statistical guidelines for nested case-control studies.

Authors:  Stuart G Baker; Barnett S Kramer; Sudhir Srivastava
Journal:  BMC Med Res Methodol       Date:  2002-02-28       Impact factor: 4.615

View more
  65 in total

Review 1.  Application of metabolomics to prostate cancer.

Authors:  Bruce J Trock
Journal:  Urol Oncol       Date:  2011 Sep-Oct       Impact factor: 3.498

Review 2.  Identification of aberrant pathways and network activities from high-throughput data.

Authors:  Jinlian Wang; Yuji Zhang; Catalin Marian; Habtom W Ressom
Journal:  Brief Bioinform       Date:  2012-01-27       Impact factor: 11.622

Review 3.  Cancer biomarkers.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Mol Oncol       Date:  2012-02-06       Impact factor: 6.603

Review 4.  Integrating predictive biomarkers and classifiers into oncology clinical development programmes.

Authors:  Robert A Beckman; Jason Clark; Cong Chen
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

5.  Biospecimens and biorepositories: from afterthought to science.

Authors:  Jimmie B Vaught; Marianne K Henderson; Carolyn C Compton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02       Impact factor: 4.254

6.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

7.  Bring on the biomarkers.

Authors:  George Poste
Journal:  Nature       Date:  2011-01-13       Impact factor: 49.962

8.  Biobanking and international interoperability: samples.

Authors:  Michael Kiehntopf; Michael Krawczak
Journal:  Hum Genet       Date:  2011-07-15       Impact factor: 4.132

9.  Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank.

Authors:  Rune Erichsen; Timothy L Lash; Stephen J Hamilton-Dutoit; Beth Bjerregaard; Mogens Vyberg; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

10.  Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles.

Authors:  Robert R Kitchen; Vicky S Sabine; Andrew H Sims; E Jane Macaskill; Lorna Renshaw; Jeremy S Thomas; Jano I van Hemert; J Michael Dixon; John M S Bartlett
Journal:  BMC Genomics       Date:  2010-02-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.